

Attorney Docket No. 5470-368

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ting et al.
Application No.: 10/511,989
Filed: May 25, 2005
Title: Caterpillar Gene Family

U.S. Patent No.: 7,569,681
Issued: August 4, 2009
Confirmation No: 4540

October 28, 2009

Commissioner for Patents
Attn: Certificate of Correction Branch
P.O. Box 1450
Alexandria, VA 22313-1450

**REQUEST FOR ENTRY OF CERTIFICATE OF CORRECTION UNDER
No. 35 U.S.C. §254 AND 37 C.F.R. §1.322**

Sir:

The Assignee of record for the above-referenced patent hereby requests, pursuant to 35 U.S.C. §254 and 37 C.F.R. §1.322, that a Certificate of Correction be issued. This request is made in order to correct the mistakes incurred through the fault of the U.S. Patent and Trademark Office. The mistakes appearing in the patent are set forth with corrections on the Certificate of Correction attached herewith. The Assignee further directs the Commissioner's attention to the CFR 1.41 (a)(1) stating the inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration. The declaration of record clearly states Jonathan A. Harton's address as "Tampa, Florida".

No fee is believed due. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,




Alice M. Bonnen
Registration No. 57,154

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATION OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on October 28, 2009.



Jessica M. French

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,572,741
APPLICATION NO.: 11/229,476
ISSUE DATE: Aug. 11, 2009
INVENTOR(S) : Das et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page:

Item 75, Inventors: Jonathan A. Harton's address "Durham NC" should read
--Tampa, FL --

Item 56, Other Publications, page 3, line 30, right column: Please add "2001." after
"Inohara, et al."

In the Patent:

Column 2, Lines 23, 24: Please correct by underlining letters as follows
-- CARD, Transcription Enhancer, R(purine)-binding, Pyrin, Lots of Leucine Repeats) --

Column 59, Line 30: Please add "IL" after "Chemical Co., Rockland,"

Rec'd PCT/PTO 25 MAY 2005

10/511989

ATTORNEY DOCKET NO. 5470-368

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled
CATERPILLER GENE FAMILY✓

the specification of which

☐ is attached hereto

OR

☒ was filed on October 21, 2004.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information that became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f), or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

Rec'd PET/PTO 25 MAY 2005
10/511989

ATTORNEY DOCKET NO. 5470-368

3-00

Full name of third inventor: Jonathan A. Harton

Inventor's
Signature: [Signature] Date: 11/15/84

Residence: Tampa, Florida FL
Durham, North Carolina, United States ←

Citizenship: United States ✓

Mailing Address: 4909 HALLOWEEN WAY
23 E. Bayberry Court
Durham, North Carolina 27713
TAMPA, FLORIDA 33647

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5470-368	Serial No. 10/511,989
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Jenny Ting et al..	
		Filing Date: May 25, 2005	Group: 1633
/SDP/	71.	Holt, et al. 2003. Resistance gene signaling in plants - complex similarities to animal innate immunity. <i>Curr Opin Immunol</i> 15:20.	
	72.	Hugot, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. <i>Nature</i> 411:599.	
	73.	Inohara, et al. 1999. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor- kappaB. <i>Journal of Biological Chemistry</i> 274:14560.	
	74.	Inohara, et al. 2000. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. <i>J Biol Chem</i> 275:27823.	
	75.	Inohara, et al. 2001. Human nod1 confers responsiveness to bacterial lipopolysaccharides. <i>J.Biol.Chem.</i> 276(4):2551-4.	
	76.	International Search Report for International Patent Application No. PCT/US03/13562 mailed on October 1, 2004	
	77.	Kaisho and Akira. 2000. Critical roles of Toll-like receptors in host defense. <i>Crit Rev Immunol</i> 20:393.	
	78.	Koonin and Aravind. 2000. The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation. <i>Trends.Biochem.Sci.</i> 25(5):223-4.	
	79.	Kretsovali, et al. 1998. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. <i>Mol.Cell Biol.</i> 18:6777.	
/SDP/	80.	Kretsovali, et al. 2001. Self-association of CIITA correlates with its intracellular localization and transactivation. <i>J.Biol.Chem.</i> 276(34):32191-7.	
	81.	Li and Verma. 2002. NF-kappaB regulation in the immune system. <i>Nat Rev Immunol</i> 2:125.	
prev. rvwd	82.	Linhoff, et al. 2001. Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains. <i>Mol.Cell Biol</i> 21(9):3001-11.	
/SDP/	83.	MacKeigan, et al. 2000. MEK inhibition enhances paclitaxel-induced tumor apoptosis. <i>J Biol Chem</i> 275:38953.	
	84.	Manji, et al. 2002. PYPAFI, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. <i>J Biol Chem</i> 277:11570.	
	85.	Martinon, et al. 2002. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. <i>Mol Cell</i> 10:417.	
	86.	Masternak, et al. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. <i>Genes and Development</i> 14:1156.	
	87.	Miceli-Richard, et al. 2001. CARD15 mutations in Blau syndrome. <i>Nat Genet</i> 29:19.	
	88.	Nelson, L. M. 2001. Autoimmune ovarian failure: comparing the mouse model and the human disease. <i>J Soc Gynecol Investig</i> 8:S55.	
	89.	Nickerson, et al. 2001. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. <i>J Biol Chem</i> 276:19089.	
/SDP/	90.	Ogura, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. <i>Nature</i> 411(6837):603-606.	

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.